EXCLUSIVE Blackwater founder Prince takes role in COVID vaccine venture Reuters 20210605
Erik Prince, the founder of controversial private
military firm Blackwater and a supporter of former President Donald Trump,
jumped into the COVID-19 business late last year with
a deal to distribute an experimental vaccine should it be approved,
according to three people familiar with the arrangement and business records
seen by Reuters.
The COVID-19 vaccine, known as UB-612, is being developed by a privately-held U.S. firm called COVAXX.
The company has said the vaccine shows promise in
protecting people against coronavirus, based on a
small study of 60 patients in Taiwan. It hasn't provided data on safety and efficacy from large clinical
trials, information that is usually required before a vaccine is authorized for
public use.
COVAXX is unrelated to the similar-sounding but
better-known "COVAX," a global vaccine distribution program backed by
the World Health Organization.
Since the start of the pandemic in 2020, the COVAXX vaccine has attracted some big-name backers,
including endorsements from entrepreneur Peter Diamandis, who co-founded the
company, and motivational speaker Tony Robbins. In March, the company raised $1.35 billion in a
private placement, according
to U.S. securities filings.
Prince's involvement in vaccine distribution,
which has not been previously reported, sheds new light on the race to profit
from the uncertainties of the pandemic. Vaccine supply deals have often been forged through direct government ties to drugmakers, global
health organizations or diplomatic channels.
Reuters couldn't determine how Prince first
became associated with COVAXX, or whether he has brokered any vaccine supply
deals.
Prince did not respond to questions for this
story. A source close to Prince said that "Erik has
been helping a vaccine manufacturer set up distribution," but declined to
give details.
Diane Murphy, a public relations consultant for
Vaxxinity Inc, which owns COVAXX, declined to answer questions related to
Prince. In a statement to Reuters, she
said that the company has "accepted
introductions from a variety of private, public and non-profit intermediaries,
both formally and informally."
'DOLLARS PER DOSE'
Prince has made headlines for years, first as
chief executive of Blackwater, whose security guards fatally shot more than a
dozen Iraqi civilians in Baghdad in 2007.
After he left Blackwater, Prince pushed to
privatize the war in Afghanistan by having contractors fight instead of the
U.S. military and became embroiled in an investigation into possible collusion
between the Trump election campaign and the Russian government.
Prince sought to recruit a close associate, the
late Paul Behrends, a former Republican congressional staffer and lobbyist who
represented Blackwater for over two years, to help in the COVAXX project.
In a series of text messages to Behrends, Prince
described the potential for profit from selling the vaccines.
"There's room for a couple dollars per dose
in commissions," Prince said in a Nov. 9 text to Behrends. He shared with Behrends a "Letter of Authorization" on COVAXX
letterhead signed by senior vice president Brandon Schurter as proof of his
distribution deal. Schurter did not respond to requests for comment.
The October 2020 letter said that an entity called
Windward Capital, with an address in Abu
Dhabi, was authorized to "assist in the process of creating distribution
networks." Reuters could not find a Windward Capital registered in Abu Dhabi. But a company called Windward Holdings
that handles "professional, scientific and technical activities" is
listed there, with Erik Prince the sole named shareholder.
Prince is also the managing member of a corporate
entity called Windward Wyoming LLC, which
says it has a "global distribution" deal with COVAXX, according to
records of non-public business agreements seen by Reuters. The company was
formed in October 2020, public incorporation records in Wyoming show.
Lawyers and other officials affiliated with the
various Windward entities did not respond to requests for comment.
Prince and Behrends were negotiating how to carve
up prospective sales territories by country, said Barry Angeline, a friend of
Behrends. But their possible collaboration was cut short in
December, when Behrends died.
Vaxxinity consultant Murphy told Reuters the company has a "focus on the developing
market" – including the many countries
that have been unable to acquire the shots made by global drugmakers and
stockpiled by wealthier nations.
HIGH-PROFILE BACKERS
COVAXX was formed in early
2020 as a subsidiary of United Biomedical Inc (UBI), a maker of diagnostic tests and veterinary
vaccines, to address the coronavirus pandemic. In April, the company
announced it was being consolidated into a new holding corporation called
Vaxxinity.
COVAXX's backers were quick to publicize the
vaccine's potential beginning in July, based on early tests in animals, and
before the first clinical trials in people began in Taiwan.
Diamandis, who is listed as a co-founder of Vaxxinity,
wrote in a July 30 post on his personal blog that the vaccine was safe for
patients and likely effective in the elderly. He told
Reuters he made it clear in those posts that his assertions were based on
previous trial results of other vaccines developed by the company.
A few weeks later, Robbins, the self-help coach,
held a webinar promoting COVAXX titled "The
most powerful vaccine you've never heard of." Robbins said in the video that he was one of the company owners. "I've invested in the company, so everyone knows. Because I've been blown away by seeing these
results," he said.
Robbins "remains an investor," his
spokeswoman Jennifer Connelly said in a statement to Reuters. She added, "Mr. Robbins is not involved in the management or daily
operations."
In October, COVAXX and shipping giant Maersk
announced a partnership to provide global transport of the vaccine as soon as
it becomes available. The Maersk official quoted in the release, Rob Townley, said the company
recognized the urgent need to safely deliver COVID-19 vaccines worldwide.
Townley was briefly an aide to former U.S. Army
general Michael Flynn during Flynn's short tenure as Trump's National Security
Adviser. In an interview, Townley said he knows Prince but couldn't discuss
Prince's involvement.
Data on how well the vaccine works is still
pending. In an email to Reuters,
Vaxxinity’s Murphy said the company had completed the
Phase 1 trial of 60 volunteers aged 20 to 55 in Taiwan, and is conducting a new study of 3,800 people there,
including teens and elderly participants. The company plans larger trials in Brazil and India later
this year.
沒有留言:
張貼留言
請網友務必留下一致且可辨識的稱謂
顧及閱讀舒適性,段與段間請空一行